Published in Diabetes Care on December 27, 2007
Emerging risk factors and markers of chronic kidney disease progression. Nat Rev Nephrol (2009) 1.58
Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care (2014) 1.47
Cellular ADMA: regulation and action. Pharmacol Res (2009) 1.42
Endogenous nitric oxide synthase inhibitors in the biology of disease: markers, mediators, and regulators? Arterioscler Thromb Vasc Biol (2012) 1.19
The use of targeted biomarkers for chronic kidney disease. Adv Chronic Kidney Dis (2010) 1.05
Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. Clin J Am Soc Nephrol (2009) 0.96
Asymmetric dimethylarginine and cardiovascular risk: systematic review and meta-analysis of 22 prospective studies. J Am Heart Assoc (2015) 0.94
Renal endothelial dysfunction in diabetic nephropathy. Cardiovasc Hematol Disord Drug Targets (2014) 0.90
Small Molecule Inhibitors of Protein Arginine Methyltransferases. Expert Opin Investig Drugs (2016) 0.89
Circulating levels of dimethylarginines, chronic kidney disease and long-term clinical outcome in non-ST-elevation myocardial infarction. PLoS One (2012) 0.88
The association of dimethylarginine dimethylaminohydrolase 1 gene polymorphism with type 2 diabetes: a cohort study. Cardiovasc Diabetol (2011) 0.87
Biomarkers in chronic kidney disease, from kidney function to kidney damage. World J Nephrol (2015) 0.82
Therapy: Vitamin B6, B9 and B12 in diabetic nephropathy--beware. Nat Rev Endocrinol (2010) 0.81
Asymmetric dimethylarginine and long-term adverse cardiovascular events in patients with type 2 diabetes: relation with the glycemic control. Cardiovasc Diabetol (2014) 0.79
Association between Body Mass Index, Asymmetric Dimethylarginine and Risk of Cardiovascular Events and Mortality in Norwegian Patients with Suspected Stable Angina Pectoris. PLoS One (2016) 0.79
Asymmetric and Symmetric Dimethylarginine as Risk Markers for Total Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Studies. PLoS One (2016) 0.79
Asymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitus. World J Exp Med (2015) 0.78
ADMA predicts major adverse renal events in patients with mild renal impairment and/or diabetes mellitus undergoing coronary angiography. Medicine (Baltimore) (2017) 0.77
Competitive interaction between fibroblast growth factor 23 and asymmetric dimethylarginine in patients with CKD. J Am Soc Nephrol (2014) 0.77
[Asymmetric dimethylarginine (ADMA): A cardiovascular risk factor]. Wien Klin Wochenschr (2008) 0.77
Real-time functional characterization of cationic amino acid transporters using a new FRET sensor. Pflugers Arch (2015) 0.76
Metabolomic Profiling of Arginine Metabolome Links Altered Methylation to Chronic Kidney Disease Accelerated Atherosclerosis. J Proteomics Bioinform (2015) 0.75
Supplementation with Phycocyanobilin, Citrulline, Taurine, and Supranutritional Doses of Folic Acid and Biotin-Potential for Preventing or Slowing the Progression of Diabetic Complications. Healthcare (Basel) (2017) 0.75
Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus. J Transl Med (2016) 0.75
Cardiovascular disease and type 1 diabetes: prevalence, prediction and management in an ageing population. Ther Adv Chronic Dis (2015) 0.75
Asymmetric Dimethylarginine and Its Relation As a Biomarker in Nephrologic Diseases. Biomark Insights (2016) 0.75
Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria. Cardiovasc Diabetol (2017) 0.75
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med (2003) 20.06
Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med (2008) 18.27
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med (2009) 12.73
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet (2010) 7.69
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med (2013) 7.54
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int (2011) 5.25
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet (2012) 5.10
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet (2012) 4.75
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int (2004) 4.51
Nephropathy in diabetes. Diabetes Care (2004) 4.08
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int (2011) 3.96
Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int (2003) 3.95
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation (2004) 3.78
Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int (2008) 3.27
Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care (2003) 3.12
Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev (2006) 3.06
Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int (2002) 2.92
Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis (2003) 2.68
Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ (2004) 2.62
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol (2007) 2.61
Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. Kidney Int (2011) 2.52
Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol (2006) 2.51
Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant (2002) 2.41
Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up study. J Hypertens (2007) 2.27
Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens (2013) 2.15
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med (2009) 2.14
Urinary proteomics in diabetes and CKD. J Am Soc Nephrol (2008) 2.12
Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens (2007) 2.12
Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Diabetes Care (2003) 2.08
Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care (2010) 2.06
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension (2011) 2.05
Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. Am J Kidney Dis (2011) 2.05
Progression of nephropathy in type 2 diabetic patients. Kidney Int (2004) 2.05
Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int (2005) 2.00
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics (2010) 1.90
Diabetic nephropathy. Diabetes Care (2003) 1.87
Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation (2011) 1.87
New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet (2012) 1.79
Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes (2009) 1.76
Reduced nitric oxide in diabetic kidneys due to increased hepatic arginine metabolism: implications for renomedullary oxygen availability. Am J Physiol Renal Physiol (2007) 1.75
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am J Cardiol (2009) 1.75
Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysis. Nephrol Dial Transplant (2005) 1.67
Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int (2012) 1.65
Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care (2002) 1.61
Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes (2004) 1.59
Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med (2010) 1.59
Low plasma concentrations of arginine and asymmetric dimethylarginine in premature infants with necrotizing enterocolitis. Br J Nutr (2007) 1.58
Modulation of asymmetric dimethylarginine in critically ill patients receiving intensive insulin treatment: a possible explanation of reduced morbidity and mortality? Crit Care Med (2005) 1.58
Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care (2002) 1.57
Dietary nitrate attenuates oxidative stress, prevents cardiac and renal injuries, and reduces blood pressure in salt-induced hypertension. Cardiovasc Res (2010) 1.53
Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy. Kidney Int (2005) 1.52
Role of the human erythrocyte in generation and storage of asymmetric dimethylarginine. Am J Physiol Heart Circ Physiol (2012) 1.52
Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care (2003) 1.51
Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant (2004) 1.49
Development and validation of GFR-estimating equations using diabetes, transplant and weight. Nephrol Dial Transplant (2009) 1.46
Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care (2005) 1.44
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. Eur Heart J (2011) 1.43
Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int (2005) 1.40
Subclinical coronary and aortic atherosclerosis detected by magnetic resonance imaging in type 1 diabetes with and without diabetic nephropathy. Circulation (2006) 1.38
A single nucleotide polymorphism within the acetyl-coenzyme A carboxylase beta gene is associated with proteinuria in patients with type 2 diabetes. PLoS Genet (2010) 1.38
Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes (2012) 1.38
Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy. Diabetes Care (2006) 1.37
Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol (2006) 1.34